{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zhang Y"],"funding":["U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)","Division of Cancer Prevention, National Cancer Institute (NCI Division of Cancer Prevention)","U.S. Department of Health &amp; Human Services | NIH | National Institute of Allergy and Infectious Diseases","NIAID NIH HHS","U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute","NHLBI NIH HHS","U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)","Division of Cancer Prevention, National Cancer Institute","NCI NIH HHS","U.S. Department of Health & Human Services | National Institutes of Health (NIH)","U.S. Department of Health &amp; Human Services | National Institutes of Health"],"pagination":["5589"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11222507"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(1)"],"pubmed_abstract":["As the new SARS-CoV-2 Omicron variants and subvariants emerge, there is an urgency to develop intranasal, broadly protective vaccines. Here, we developed highly efficacious, intranasal trivalent SARS-CoV-2 vaccine candidates (TVC) based on three components of the MMR vaccine: measles virus (MeV), mumps virus (MuV) Jeryl Lynn (JL1) strain, and MuV JL2 strain. Specifically, MeV, MuV-JL1, and MuV-JL2 vaccine strains, each expressing prefusion spike (preS-6P) from a different variant of concern (VoC), were combined to generate TVCs. Intranasal immunization of IFNAR1<sup>-/-</sup> mice and female hamsters with TVCs generated high levels of S-specific serum IgG antibodies, broad neutralizing antibodies, and mucosal IgA antibodies as well as tissue-resident memory T cells in the lungs. The immuni"],"journal":["Nature communications"],"pubmed_title":["Three SARS-CoV-2 spike protein variants delivered intranasally by measles and mumps vaccines are broadly protective."],"pmcid":["PMC11222507"],"funding_grant_id":["P01 AI112524","AI145144","R01 AI090060","R01 AI157205","P01 AI175399","AI42733","R01 AI130110","AI093848","R21 AI180667","T32 AI165391","AI112524","R01 HL168501","AI157205","U54CA260582","T32AI165391","R01 AI093848","AI175399","U19 AI142733","AI090060","U54 CA260582","R01 AI145144"],"pubmed_authors":["Hall JM","Yount JS","Thongpan I","Gupta YA","Martinez-Sobrido L","Li J","Liang X","Kc M","Ye C","Evans JP","Liu SL","Peeples ME","Xu J","Yoo SJ","Hsu CC","Qu P","Lu M","Chamblee M","Zhang Y","Dubey P","Shamseldin MM","Misny J","Boyaka PN"],"additional_accession":[]},"is_claimable":false,"name":"Three SARS-CoV-2 spike protein variants delivered intranasally by measles and mumps vaccines are broadly protective.","description":"As the new SARS-CoV-2 Omicron variants and subvariants emerge, there is an urgency to develop intranasal, broadly protective vaccines. Here, we developed highly efficacious, intranasal trivalent SARS-CoV-2 vaccine candidates (TVC) based on three components of the MMR vaccine: measles virus (MeV), mumps virus (MuV) Jeryl Lynn (JL1) strain, and MuV JL2 strain. Specifically, MeV, MuV-JL1, and MuV-JL2 vaccine strains, each expressing prefusion spike (preS-6P) from a different variant of concern (VoC), were combined to generate TVCs. Intranasal immunization of IFNAR1<sup>-/-</sup> mice and female hamsters with TVCs generated high levels of S-specific serum IgG antibodies, broad neutralizing antibodies, and mucosal IgA antibodies as well as tissue-resident memory T cells in the lungs. The immuni","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2026-07-15T09:55:35.089Z","creation":"2025-04-04T12:21:57.787Z"},"accession":"S-EPMC11222507","cross_references":{"pubmed":["38961063"],"doi":["10.1038/s41467-024-49443-2"]}}